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Purpose: This investigation was carried out to determine if a solid dispersion of furosemide in sodium 
starch glycolate (SSG) would enhance the dissolution properties of the drug. 
Methods: Solid dispersion of furosemide in SSG was prepared in ratios of 1:1 and 1 (furosemide):2 
(SSG) by kneading method. In each case, the solid dispersion was characterized by Fourier transform 
infrared (FTIR) spectroscopy, differential scanning calorimetry (DSC), and X-ray diffraction (XRD) to 
ascertain if there were any physicochemical interactions between drug and carrier that could affect 
dissolution. Tablets containing the solid dispersion were formulated and their dissolution characteristics 
compared with commercial furosemide tablets. The dissolution studies were performed at 37 ± 0.5
o
C 
and 50 rpm in simulated gastric fluid (pH 1.2).  
Results: FTIR spectroscopy, DSC, and XRD showed a change in crystal structure toward an 
amorphous form of furosemide. Dissolution data indicated that furosemide dissolution was enhanced. 
XRD, DSC, FTIR spectroscopy and dissolution studies indicated that the solid dispersion formulated in 
1:2 ratio showed a 5.40-fold increase in dissolution and also exhibited superior dissolution 
characteristics to commercial furosemide tablets. 
Conclusion:  Solid dispersion technique can be used to improve the dissolution of furosemide. 
 
 










*Corresponding author: Tel.  +91-9923968989, Fax +91-2115-222213, E-mail- ganesh_chaulang@rediffmail.com                                       
Chaulang et al  
Trop J Pharm Res February 2009; 8 (1): 44 
INTRODUCTION 
 
Furosemide (FRMD) is 5-(aminosulphonyl)-4-
chloro-2-[(2-fuanyl-methyl) amino] benzoic 
acid, and it is a potent high ceiling (loop) 
diuretic mainly used in the treatment of 
hypertension
1
. The drug has been classified 
as a class IV drug as per the 
biopharmaceutical classification system (BCS) 
as a result of its low solubility and oral 
bioavailability; one of the major causes of its 




Oral bioavailability of a drug depends on its 
solubility and/or dissolution rate, and 
dissolution may be the rate determining step 
for the onset of therapeutic activity. Therefore 
efforts to increase drug dissolution of drug are 
often needed. Methods available to improve 
dissolution include salt formation, 
micronization and addition of solvent or 
surface active agents. Solid dispersion (SD) is 
one of such methods and it involves a 
dispersion of one or more active ingredients in 
an inner carrier or matrix in solid state 
prepared by melting, dissolution in solvent or 
melting-solvent method
4
. The technique has 
been used for a wide variety of poorly 













. SD technology has been 
successfully been used for improving the 














The present work aims to evaluate the 
potential of the solid dispersion technique for 
development of fast-dissolving tablets of 
FRMD using SSG as the hydrophilic carrier. 
Furthermore, this study seeks to investigate 
kneading as a method for the preparation of 
these binary systems as well as their solid 
state characterization by employing analytical 
tools such as Fourier Transform infrared 
(FTIR), X-ray diffraction (XRD) and differential 
scanning calorometry (DSC). Furthermore, the 









Furosemide (FRMD) was gift sample from 
Samruddha Pharmaceuticals, Thane, 
Mumbai, and sodium starch glycolate (SSG) 
was obtained from Loba Cheime, India. 
Ethanol, Avicel PH102 and Crosscarmellose 
sodium were purchased from Suchem Lab, 
Ahemadabad. 
 
Preparation of furosemide-SSG solid 
dispersion 
 
A mixture (6g) of furosemide and SSG (1:1 
and 1:2 by weight, respectively) was wetted 
with water-ethanol (1:1 ratio) till the slurry was 
formed  and kneaded thoroughly for 60 min in 
a glass mortar. The paste formed was dried 
under vacuum (Conaform Vaccume dryer, 
Patterson Industries, Canada.) for 24 h. The 
resulting powder was passed through sieve 
no. 60 (B.P. 2003) and stored in a desiccator 
until further evaluation. Physical mixtures (PM, 
6g) were also obtained by pulverizing and 
carefully mixing furosemide and SSG (1:1 and 
1:2 ratio by weight, respectively) in a glass 
mortar. After a preliminary evaluation, it was 
found that solid dispersion prepared by 
kneading in 1:2 (furosemide: SSG) ratio 
showed higher dissolution; therefore, this solid 
dispersion was used for the preparation of 
tablet formulations.   
  
Fourier transform infrared (FTIR) spectro-
scopy  
 
FTIR spectra were recorded on samples 
prepared in potassium bromide (KBr) disks 
using a Shimadzu Corporation (Koyto, Japan) 
facilty (model - 8400S). Samples were 
prepared in KBr disks in a hydrostatic press at 
6-8 tons pressure. The scanning range was 
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Differential scanning calorimetry (DSC) 
 
DSC analysis was performed using METTLER 
DSC 30S, Mettler Toledo India Pvt. Ltd., 
Swizerland, using crucible Al 40µL, at of 10
0
C 
/min heating rate, under nitrogen environment. 




X-ray diffraction (XRD) 
 
X-ray powder diffraction patterns were 
recorded on an X-ray powder diffraction 
system (PANalytical Spectris Pvt. Ltd, 
Singapore) using copper target, a voltage of 
40 Kv and a current of 30 mA. The scanning 
was done over 2θ range of 5º to 60º. 
 
Dissolution rate studies 
 
The dissolution was studied with accurately 
weighed amount of the formulations 
(containing approx. 40 mg of furosemide) 
using a USP apparatus II in 900 ml of 
simulated gastrointestinal fluid (SGF, pH 1.2) 
for one hour. The rotational speed of the 
paddle was set at 50 rpm at 37 ± 0.5ºC. 
Aliquots (5ml each) were withdrawn at 
predetermined time intervals for 1h; sink 
conditions were maintained. The samples 
were analyzed for drug content using a double 
beam UV spectrophotometer (model no. UV 
2401 PC, Shimadzu Corporation, Koyto, 
Japan) at 274 nm 
 
Tablet preparation and characterization 
 
Tablets containing an equivalent of 40 mg of 
furosemide (SD2) were compressed on a 16-
station single rotary tabletting press (Type – 
CMD3 – 16, Cadmach Machinery Pvt. Ltd., 
Ahemadabad) using an 8-mm standard flat 
punch by direct compression technique, at a 
compression pressure of 6 tons.  Tablet 
formulations were code as MD1, MD2 and 
MD3.  MD1 tablets contain 80 mg of solid 
dispersion two (SD2), 119 mg of Avicel PH102 
and 1 mg of magnesium stearate. MD2 tablets 
contain the same amount of furosemide and 
magnesium stearate as MD1 plus 99 mg of 
Avicel PH102 and 20 mg of Crosscarmellose 
sodium. MD3 tablets contain same amount of 
furosemide and magnesium stearate as MD1 
plus 89 mg of Avicel PH102 and 40 mg of 
Crosscarmellose sodium. The tablets were 
evaluated for hardness (Tablet hardness 
tester, model no. C–WWTDH 500N, Campbell 
Electronics, Mumbai), friability (Roche 
Friabilator), weight variation, and drug 
content. In vitro dissolution studies on MD3 
tablets and two commercial tablets of 
furosemide containing 40mg of furosemide - 
formulation A (Lasix
®
) and formulation B 
(Salinex
®
), respectively - were carried out in 
900mL of SGF (pH-1.2) as the dissolution 






IR spectra of furosemide and its binary 
systems with SSG are presented in Figure 1. 
Pure furosemide spectra showed sharp 
characteristic peaks at 3400.27, 3122.54, 
1665, and 1560 cm
–1
. The above 
characteristic peaks appear in the spectra of 
all binary systems at the same wave number 
indicating no interaction between the drug and 
the carrier (SSG). 
 
Differential scanning calorimetry (DSC) 
 
DSC thermograms of furosemide, SSG as 
well as their solid dispersions prepared by 
kneading method and physical mixing are 
shown in Figure 2. Furosemide exhibited a 
characteristic, sharp exothermic peak at 224.8 
o
C which is associated with the melting point 
of the drug and indicates the crystalline nature 
of the drug; degradation was indicated by an 
endothermic peak at 280.2 
o
C. However, the 
characteristic exothermic peak, corresponding 
to drug melting was broadened and shifted 
toward a higher temperature with reduced 
intensity in both physical mixtures and solid 
dispersions. DSC studies also showed that 
there no interaction between drug and carrier 
at a molecular level in both the solid 
dispersions and physical mixtures. 
 
Chaulang et al  
Trop J Pharm Res February 2009; 8 (1): 46 
 
 
Figure 1:   FTIR spectra of furosemide alone and with various binary mixture of SSG. 
FMRD = Furosemide; PM1 = Physical Mixture One (1:1 ratio); PM2 = Physical   Mixture Two 
(1:2 ratio); SD1 = Solid Dispersion One (1:1 ratio); SD2 = Solid Dispersion Two (1:2 ratio)  
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X-ray diffraction 
 
The x,-ray diffraction pattern of frusemide 
exhibited sharp, highly intense and less 
diffused peaks indicating the crystalline nature 
of drug, as shown in Figure 3. It showed 
diffraction peaks at 2θ degree of 12, 18, 18.9, 
23, 24.7 and 28.6. However the x-ray 
diffraction patterns of the physical mixture and 
solid dispersion were simply a superimposition 
of each component with with respect to the 
peaks of frusemide. Moreover, the relative 
intensity and 2θ angle of these peaks 
remained practically unchanged. Thus, there 
was no amorphization of the drug and which 
still retained its original crystalline form. IR and 
DSC studies support the same hypothesis, 




The dissolution profiles of the pure drug, 
carrier (SSG) and binary systems are 
presented in Figure 4. It is evident that the 
solid dispersion (SD) technique improved the 
dissolution rate of the drug to a great extent. 
The results indicate that SD2 (79% of drug 
dissolved in 60 min) showed the highest 
dissolution rate, followed by SD1 with 65% of 
drug dissolved over the same period. Physical 
mixtures (PM) also improve dissolution rate 
significantly (P <0.05) compared with the drug 
alone. The order of dissolution rate is SD2 > 
SD1 > PM2 > PM1 > drug alone.  
 
To formulate a tablet of furosemide, the SD2 
binary mixture was selected based on its in 
vitro dissolution performance. MD3 tablets 
showed the fastest disintegration (89 seconds) 
and this is attributed to inclusion of the 
disintegrant, Crosscarmellose sodium, in the 
formulation. In vitro dissolution studies for 
MD3 confirmed the results obtained with solid 
binary mixtures. MD3 tablets, like the 
corresponding binary mixture, showed good 
dissolution (73.9% in 60 min). When 
compared with commercial tablets of 
furosemide (see Figure 5), MD3 tablets were 








The solid dispersion was prepared and 
characterized and the results showed that 1:2 
solid dispersion (SD2) had a higher dissolution 
profile compared to other formulations. As 
shown in FTIR spectroscopic studies, the 
spectra of pure drug, furosemide and solid 
dispersion were similar and the peak for pure 
furosemide was also appeared in all the 
spectra of the binary mixtures. Thus, there 
was no interaction between the drug and the 
carrier (SSG). DSC studies, on the basis of 
the melting peak of furosemide (224.8 
o
C), 
also indicate that there was not interaction 
between the drug and carrier. However, the 
characteristic melting peak broadened and 
shifted toward a higher temperature with 
reduced intensity for both the physical 
mixtures as well as solid dispersions. This 
may be attributed to high polymer 
concentration and uniform distribution of the 
drug in the crust of the polymer, resulting in 
complete miscibility of the molten drug in the 
polymer. The similarity in the DSC of the solid 
dispersions and physical mixtures suggests 
that the kneading process did not induce 
interaction at the molecular level neither did 
the solid dispersion which is a physical 
mixture with the drug crystals highly dispersed 
in the carrier. This was further confirmed by 
XRD data. In diffractograms, the peak position 
(angle of diffraction) is indicative of a crystal 
structure and the peak height is a measure of 
the sample crystallinity. The diffractograms of 
pure furosemide and pure SSG exhibited a 
series of intense peaks which are indicative of 
their crystallinity. The diffractogram of physical 
mixture was practically a simple superposition 
of each component, indicating the presence of 
furosemide in a crystalline state and no 
formation of a new structure. This result 
supports the finding of FTIR spectra. 
 
The solid dispersions (1:1 and 1:2 ratios) 
prepared showed a reduction in sharpness of 
the XRD peak intensity with the peak intensity 
of 1:2 solid dispersion lower than the other. 
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Figure 4: Dissolution profiles of furosemide and its binary systems with SSG. 




Figure 5: Dissolution profiles of tablets containing solid dispersion and commercial tablets.  
   (■) – Formulation A; (▲) – Formulation B; (♦) – MD 3 
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This suggests that part of the drug structure 
may have been converted to the amorphous 
state, and this probably explains why the 
dissolution of the drug was increased. The 
order of dissolution rate is SD2 > SD1 > PM2 
> PM1 > FRMD. Enhancement of the 
dissolution of furosemide from the solid 
dispersions can be ascribed to several 
factors
14,15
 which affect the mechanism of 
dissolution rate improvement in solid 
dispersion. Lack of crystallinity, i.e., 
amorphization, increased wettability and 
dispersibility and particle size reduction are 
considered to be important factors for 
dissolution rate enhancement. As indicated by 
the dissolution data of the physical mixtures, 
improvement could be attributed to higher 
wettability and dispersibility. Dry mixing of 
drug with a hydrophilic carrier results in 
greater wetting and increases surface 
available for dissolution by reducing interfacial 
tension between hydrophobic drug and 
dissolution media. During dissolution studies, 
it was noted that drug carrier systems sank 
immediately, whereas the pure drug keeps 
floating on the surface for a longer time 
interval. MD3 tablets showed higher 
dissolution than the commercial frusemide 
tablets. Superdisintegrants accelerate 
disintegration of tablets by virtue of their ability 
to absorb a large amount of water when 
exposed to an aqueous environment. The 
absorption of water results in the breaking of 
tablets and therefore faster disintegration. 





This study shows that the dissolution rate of 
furosemide can be enhanced cosiderably by 
formulating in it as a solid dispersion in SSG 
using a kneading method. Incorporation of 
superdisintegrants in the solid dispersions 
played a critical role in dissolution 
enhancement. It may be feasible to prepare 
suitable formulations of frusemide solid 
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